News Releases

Search by year or by keyword :

Date	Title
2021-08-16	Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives.
2021-06-14	Ainos Named Exclusive Sales Partner for COVID-19 Antigen Rapid Test Kit in Taiwan.
2021-05-24	Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to "AIMD", Engages Firm to Explore Listing Requirements of National Securities Exchanges.
2021-04-21	Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to "Ainos, Inc."
2020-12-30	Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth.
2020-09-10	Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board.
2020-08-13	Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics.
2020-02-13	Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications.
2019-07-29	Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement
2018-08-23	Amarillo Biosciences First-Half 2018 Business Update.

United States:

Taiwan: